Effects of Eperisone Hydrochloride and Non-Steroid Anti-Inflammatory Drugs (NSAIDs) for Acute Non-Specific Back Pain with Muscle Spasm: A Prospective, Open-Label Study.
comparison
eperisone hydrochloride
low back pain
pain reduction
Journal
Drug, healthcare and patient safety
ISSN: 1179-1365
Titre abrégé: Drug Healthc Patient Saf
Pays: New Zealand
ID NLM: 101544775
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
08
2020
accepted:
20
10
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
26
11
2020
Statut:
epublish
Résumé
Low back pain (LBP) occurs as a common condition and may harm the patient's quality-of-life. Non-steroid anti-inflammatory drugs (NSAIDs) and eperisone form a drug regiment that has been reported as effective in improving low back pain, yet the evidence for its efficacy and safety is lacking. The aim of this study was to evaluate the effect of eperisone hydrochloride and ibuprofen compared with ibuprofen alone in reducing symptoms of patients with acute non-specific back pain with a muscle spasm. This was an open-label, prospective study involving 100 subjects with symptoms of back pain and muscle spasm. Eligible participants were randomly allocated to an experimental group (54 patients) and a control group (46 patients). The experimental group received eperisone 50 mg three times daily + ibuprofen 400 mg twice daily, and the control group received ibuprofen 400 mg twice daily over a 4-week duration. The primary outcomes were measured with the visual analog scale (VAS), and finger-to-floor (FTF) distance at baseline, week 2, and week 4. After 4 weeks of follow-up, results from 59 subjects were collected. In both groups, VAS and FTF were decreased compared to baseline. Clinically significant pain reduction (>50% than baseline) was observed to be higher in the experimental group compared with the control group in the fourth week (72.4% vs 46.7%, The combination of eperisone hydrochloride and ibuprofen effectively reduces pain and improves functional outcomes over ibuprofen alone with a similar safety profile in these patients with acute non-specific back pain with muscle spasm.
Sections du résumé
BACKGROUND
BACKGROUND
Low back pain (LBP) occurs as a common condition and may harm the patient's quality-of-life. Non-steroid anti-inflammatory drugs (NSAIDs) and eperisone form a drug regiment that has been reported as effective in improving low back pain, yet the evidence for its efficacy and safety is lacking.
OBJECTIVE
OBJECTIVE
The aim of this study was to evaluate the effect of eperisone hydrochloride and ibuprofen compared with ibuprofen alone in reducing symptoms of patients with acute non-specific back pain with a muscle spasm.
METHODS
METHODS
This was an open-label, prospective study involving 100 subjects with symptoms of back pain and muscle spasm. Eligible participants were randomly allocated to an experimental group (54 patients) and a control group (46 patients). The experimental group received eperisone 50 mg three times daily + ibuprofen 400 mg twice daily, and the control group received ibuprofen 400 mg twice daily over a 4-week duration. The primary outcomes were measured with the visual analog scale (VAS), and finger-to-floor (FTF) distance at baseline, week 2, and week 4.
RESULTS
RESULTS
After 4 weeks of follow-up, results from 59 subjects were collected. In both groups, VAS and FTF were decreased compared to baseline. Clinically significant pain reduction (>50% than baseline) was observed to be higher in the experimental group compared with the control group in the fourth week (72.4% vs 46.7%,
CONCLUSION
CONCLUSIONS
The combination of eperisone hydrochloride and ibuprofen effectively reduces pain and improves functional outcomes over ibuprofen alone with a similar safety profile in these patients with acute non-specific back pain with muscle spasm.
Identifiants
pubmed: 33235514
doi: 10.2147/DHPS.S278467
pii: 278467
pmc: PMC7678690
doi:
Types de publication
Journal Article
Langues
eng
Pagination
221-228Informations de copyright
© 2020 Pinzon et al.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2012 Feb 4;379(9814):482-91
pubmed: 21982256
Adv Ther. 2008 Oct;25(10):1010-8
pubmed: 18836866
Stat Med. 1987 Sep;6(6):657-65
pubmed: 2961039
Eur Rev Med Pharmacol Sci. 2008 Jul-Aug;12(4):229-35
pubmed: 18727454
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52
pubmed: 22588748
Arch Phys Med Rehabil. 2001 Nov;82(11):1566-70
pubmed: 11689977
Arch Phys Med Rehabil. 2012 Dec;93(12):2210-5
pubmed: 22555005
Wien Klin Wochenschr. 2019 Nov;131(21-22):541-549
pubmed: 31493101
Clin Ther. 1990 Mar-Apr;12(2):125-31
pubmed: 2141299
J Postgrad Med. 2011 Oct-Dec;57(4):278-85
pubmed: 22120855
Pharmacol Rep. 2016 Oct;68(5):903-12
pubmed: 27371896
Methods Find Exp Clin Pharmacol. 1999 Apr;21(3):209-13
pubmed: 10389124
J Rheumatol. 2007 Aug;34(8):1674-83
pubmed: 17611989
Adv Ther. 2009 May;26(5):563-73
pubmed: 19458926